Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra
- 1 January 2016
- journal article
- Published by Elsevier BV in Toxicology Letters
- Vol. 243, 7-21
- https://doi.org/10.1016/j.toxlet.2015.12.005
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s diseaseFrontiers in Cellular Neuroscience, 2014
- Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolismJournal of Neurochemistry, 2013
- Bee Venom and Its Component Apamin as Neuroprotective Agents in a Parkinson Disease Mouse ModelPLOS ONE, 2013
- Neurotoxin-based models of Parkinson's diseaseNeuroscience, 2012
- α-Synuclein misfolding and Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Are synucleinopathies prion-like disorders?The Lancet Neurology, 2010
- Air pollution: mechanisms of neuroinflammation and CNS diseaseTrends in Neurosciences, 2009
- Oligomeric α-synuclein inhibits tubulin polymerizationBiochemical and Biophysical Research Communications, 2007
- α-Synuclein Expression Modulates Microglial Activation PhenotypeJournal of Neuroscience, 2006
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003